Trial Profile
Hydralazine/isosorbide dinitrate in African-American patients with moderate-to-severe heart failure also on standard treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2012
Price :
$35
*
At a glance
- Drugs Hydralazine/isosorbide dinitrate (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms A-HeFT
- 27 Mar 2012 Results reporting hospital readmission and time to hospital readmission endpoints presented at the 61st Annual Scientific Session of the American College of Cardiology.
- 05 Nov 2010 New trial record.